```html

X‑ray Induced Skin Injury

Overview

X‑ray induced skin injury, also known as radiation dermatitis or radiation‑induced skin injury (RISI), refers to the damage that occurs to the epidermis, dermis, or subcutaneous tissue after exposure to ionising radiation from diagnostic or therapeutic X‑ray sources. While the skin is the most superficial organ and therefore the most readily affected, the severity of injury ranges from transient redness (erythema) to severe ulceration and necrosis.

Who it affects: The condition can affect anyone who receives a high dose of ionising radiation to the skin, most commonly:

• Patients undergoing interventional radiology or fluoroscopy‑guided procedures (e.g., cardiac catheterisation, endovascular aneurysm repair).
• Patients receiving radiotherapy for cancer, particularly when large fields or boost doses are used.
• Occupationally exposed workers (interventional cardiologists, radiologic technologists) who exceed recommended cumulative skin dose limits.
• Rarely, individuals exposed to accidental or occupational over‑exposure (e.g., radiation accidents).

According to the CDC, approximately 2–3 % of patients undergoing complex fluoroscopic procedures develop clinically significant skin injury, and up to 10 % of patients receiving high‑dose radiotherapy for head‑and‑neck cancers show some degree of dermatitis. The true incidence is likely under‑reported because mild cases often resolve without medical attention.

Symptoms

Skin injury from X‑ray exposure can manifest in a spectrum of clinical findings. The onset and severity depend on the total absorbed dose, dose‑rate, fractionation, and individual susceptibility.

Early (Acute) Phase – 24 hours to 2 weeks

• Erythema: Redness similar to a sunburn, often the first sign. May be patchy or conform to the radiation field.
• Dry desquamation: Peeling or flaking of the outer skin layer without exudate.
• Warmth & tenderness: A sensation of heat or mild pain when touched.
• Pruritus: Itching that can become bothersome.

Intermediate Phase – 2 weeks to 2 months

• Moist desquamation: Weeping, blister‑like patches that may ooze serous fluid.
• Edema: Swelling of the affected area.
• Pain: Burning or stinging sensations; pain may limit movement if over a joint.

Late (Chronic) Phase – >2 months

• Hypopigmentation or hyperpigmentation: Lightening or darkening of the skin.
• Telangiectasia: Visible small blood vessels.
• Fibrosis: Thickened, leathery skin that may restrict mobility.
• Ulceration/necrosis: Full‑thickness tissue loss exposing deeper structures; may develop fistulas.
• Secondary infection: Bacterial colonisation of ulcerated areas, presenting with increased redness, purulent discharge, fever.

Causes and Risk Factors

Direct Causes

• High‑dose diagnostic procedures: Prolonged fluoroscopy, X‑ray angiography, CT‑guided interventions.
• Therapeutic radiotherapy: External beam radiation, brachytherapy, stereotactic radiosurgery.
• Accidental over‑exposure: Equipment malfunction, mis‑placement of the beam, exposure to stray radiation.

Risk Factors

• Cumulative skin dose: Exceeding 2 Gy (Gray) in a single exposure markedly raises the risk of ulceration; doses > 5 Gy are considered severe.
• Age: Elderly patients have slower skin regeneration.
• Comorbidities: Diabetes, peripheral vascular disease, connective‑tissue disorders, and immunosuppression impair healing.
• Smoking: Vasoconstriction reduces tissue oxygenation.
• Skin type: Fair skin (Fitzpatrick I–II) is more radiosensitive.
• Concurrent chemotherapy or targeted agents: Certain drugs (e.g., taxanes, EGFR inhibitors) act as radiosensitisers.
• Poor positioning or lack of shielding: Inadequate use of lead aprons, pads, or collimation increases dose to normal skin.

Diagnosis

Diagnosing X‑ray induced skin injury involves a combination of clinical assessment, dose documentation, and occasionally ancillary tests.

Clinical Evaluation

• Detailed history of radiation exposure: type of procedure, date, estimated skin dose (if available), and any protective measures used.
• Physical exam of the skin lesion: description of size, depth, borders, presence of vesicles, ulceration, or necrosis.

Imaging and Tests

• Photographic documentation: Baseline and follow‑up photos aid in tracking healing.
• Skin dosimetry: When possible, retrospective dose reconstruction using fluoroscopy logs, dose‑area product (DAP), or treatment planning software.
• Biopsy: Reserved for atypical lesions, persistent ulceration, or suspicion of malignancy; histology shows epidermal loss, dermal fibrosis, and vascular changes.
• Microbiological culture: If infection is suspected (purulent discharge, increasing pain, systemic signs).

Classification Systems

Several grading scales help standardise severity, the most common being the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) and the Radiation Therapy Oncology Group (RTOG) skin toxicity scale. These range from Grade 1 (mild erythema) to Grade 4 (ulceration/necrosis).

Treatment Options

Management is tailored to the injury grade, patient comorbidities, and the presence of infection.

General Principles

• Prompt identification and cessation of further high‑dose exposure.
• Maintain a moist wound environment to promote epithelialisation.
• Prevent secondary infection with meticulous hygiene.
• Address pain and inflammation early.

For Acute Mild Injuries (Grade 1–2)

• Topical emollients: Aloe‑vera gel, zinc oxide ointments, or silicone‑based creams to keep skin hydrated.
• Cold compresses: 10‑15 minutes, several times daily, for erythema and pain.
• Analgesia: Acetaminophen or NSAIDs (if no contraindication).
• Education: Avoid sun exposure and abrasive clothing over the affected area.

For Moderate Injuries (Grade 3 – moist desquamation)

• Advanced dressings: Hydrocolloid, hydrogel, or silver‑impregnated dressings to manage exudate and reduce infection risk.
• Topical corticosteroids: Low‑potency (e.g., 1 % hydrocortisone) applied for 7‑10 days to reduce inflammation, if no infection.
• Systemic analgesics: Short course of oral opioids for severe pain, titrated to the lowest effective dose.

For Severe Injuries (Grade 4 – ulceration/necrosis)

• Debridement: Surgical removal of necrotic tissue under sterile conditions.
• Negative‑pressure wound therapy (NPWT): Improves perfusion and granulation tissue formation.
• Hyperbaric oxygen therapy (HBOT): 2–3 ATA for 60‑90 minutes, 20–30 sessions, can accelerate healing of radiation‑induced ulcers (supported by NIH 2022).
• Systemic antibiotics: Guided by culture results for confirmed infection.
• Skin grafting or flap reconstruction: Considered when large defects fail to close spontaneously.

Adjunctive Therapies

• Topical growth factors: Becaplermin (recombinant PDGF) has shown benefit in chronic radiation ulcer healing.
• Pentoxifylline + Vitamin E regimen: May reduce fibro‑proliferative complications (supported by a Cleveland Clinic review, 2020).

Living with X‑ray Induced Skin Injury

Daily Skin Care

• Clean the area gently with mild, fragrance‑free soap and lukewarm water.
• Pat dry; do not rub.
• Apply prescribed dressings or ointments as directed, typically once or twice daily.
• Cover the lesion with a sterile, non‑adhesive dressing if it will be exposed to friction.

Pain Management

• Schedule regular analgesic dosing rather than “as needed” to avoid breakthrough pain.
• Consider non‑pharmacologic methods: cool packs, relaxation techniques, and gentle range‑of‑motion exercises (if joint involvement).

Nutrition & Hydration

• Protein‑rich diet (1.2–1.5 g/kg/day) supports tissue repair.
• Vitamin C (500 mg daily) and zinc (15‑30 mg) are helpful for wound healing.
• Stay well‑hydrated to maintain skin turgor.

Monitoring & Follow‑up

• Weekly visual inspection for signs of infection or worsening necrosis.
• Document size changes using a ruler or transparent grid.
• Keep scheduled appointments with your radiation oncologist or wound‑care specialist.

Psychosocial Aspects

Visible skin changes can cause anxiety or depression. Seek counseling, support groups, or mental‑health services if you feel distressed. Peer‑led cancer‑survivor groups often discuss radiation skin changes and coping strategies.

Prevention

• Adhere to dose limits: The International Commission on Radiological Protection (ICRP) recommends a cumulative skin dose < 2 Gy for any single procedure.
• Use protective shielding: Lead aprons, thyroid collars, and skin‑dose‑spacer pads during fluoroscopic procedures.
• Collimation and pulsed fluoroscopy: Narrow the X‑ray beam to the smallest field and use the lowest frame rate compatible with image quality.
• Real‑time dosimetry: Place skin dose probes (e.g., MOSFET sensors) on the patient when high‑dose procedures are anticipated.
• Patient positioning: Rotate the beam or patient’s limb to distribute dose over a larger skin surface.
• Pre‑procedure counseling: Inform patients of potential skin effects and encourage them to report early symptoms.
• Radiation‑sparing techniques: In radiotherapy, employ intensity‑modulated radiation therapy (IMRT) or volumetric‑modulated arc therapy (VMAT) to minimise hot spots.

Complications

If left untreated or inadequately managed, X‑ray induced skin injury can lead to:

• Chronic non‑healing ulcers: May persist for months, requiring surgical intervention.
• Secondary bacterial or fungal infection: Can progress to cellulitis, sepsis, or osteomyelitis if deep structures are involved.
• Radiation‑induced fibrosis: Restrictive contractures limiting joint mobility, especially in the neck, axilla, or groin.
• Telangiectasia and telangiectatic bleeding: Small vessels become fragile and may bleed with minor trauma.
• Carcinogenesis: Long‑term risk of radiation‑associated skin cancer (typically basal cell carcinoma) is low but documented after cumulative doses > 20 Gy.
• Psychological impact: Persistent disfigurement can affect self‑esteem and quality of life.

When to Seek Emergency Care

References

• Mayo Clinic. “Radiation skin reaction.” mayoclinic.org. Accessed May 2026.
• Centers for Disease Control and Prevention. “Radiation Emergency Preparedness.” cdc.gov. 2024.
• National Cancer Institute. “Common Terminology Criteria for Adverse Events (CTCAE) v5.0.” 2023.
• NIH National Library of Medicine. “Hyperbaric oxygen therapy for radiation‑induced injury.” PubMed PMID: 29902307, 2022.
• Cleveland Clinic. “Management of Radiation‑Induced Skin Toxicity.” 2020.
• World Health Organization. “Ionising radiation, health effects and protective measures.” 2021.

```